InvestmentAug 4, 2026, 07:12 AM
Camp4 Therapeutics Closes Second Tranche of $100.2M Private Placement
AI Summary
Camp4 Therapeutics announced the second closing of its previously disclosed private placement, raising approximately $50.1 million in gross proceeds. This brings the total gross proceeds from the private placement to about $100.2 million. The second closing was triggered by the company receiving clearance from Australia's Therapeutic Goods Administration and Human Research Ethics Committee to initiate a Phase 1/2 clinical trial for CMP-002, its investigational product for SYNGAP1-related disorder. The funds will be used to support the continued development of CMP-002 and the company's early-stage pipeline.
Key Highlights
- Second closing of private placement generated $50.1 million in gross proceeds.
- Total private placement proceeds reached approximately $100.2 million.
- Issued 10,756,498 common shares at $1.53 per share in second closing.
- Issued 21,925,368 pre-funded warrants at $1.5299 per warrant in second closing.
- Proceeds to fund advancement of CMP-002 and early-stage pipeline.
- Received Australian TGA and HREC clearance for Phase 1/2 clinical trial of CMP-002.
Price Impact
More from CAMP